Ultragenyx Pharmaceutical Inc.’s recently made public that its EVP and Chief Medical Officer Crombez Eric unloaded Company’s shares for reported $15456.0 on May 02 ’24. In the deal valued at $43.66 per share,354 shares were sold. As a result of this transaction, Crombez Eric now holds 48,431 shares worth roughly $2.08 million.
Then, Crombez Eric sold 142 shares, generating $6,262 in total proceeds. Upon selling the shares at $44.10, the EVP and Chief Medical Officer now owns 48,785 shares.
Before that, Kassberg Thomas Richard sold 11,509 shares. Ultragenyx Pharmaceutical Inc. shares valued at $574,644 were divested by the CBO & EVP at a price of $49.93 per share. As a result of the transaction, Kassberg Thomas Richard now holds 252,823 shares, worth roughly $10.87 million.
RBC Capital Mkts initiated its Ultragenyx Pharmaceutical Inc. [RARE] rating to an Outperform in a research note published on April 22, 2024; the price target was $77. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early December with a ‘”an Overweight”‘ rating. Evercore ISI revised its rating on June 06, 2023. It rated RARE as “an Outperform” which previously was an “an In-line”.
Price Performance Review of RARE
On Monday, Ultragenyx Pharmaceutical Inc. [NASDAQ:RARE] saw its stock jump 0.61% to $43.01. Over the last five days, the stock has lost -2.29%. Ultragenyx Pharmaceutical Inc. shares have fallen nearly -10.06% since the year began. Nevertheless, the stocks have fallen -6.11% over the past one year. While a 52-week high of $54.98 was reached on 03/01/24, a 52-week low of $31.52 was recorded on 04/19/24. SMA at 50 days reached $47.18, while 200 days put it at $42.10. A total of 1.09 million shares were traded, compared to the trading of 0.81 million shares in the previous session.
Levels Of Support And Resistance For RARE Stock
The 24-hour chart illustrates a support level at 42.17, which if violated will result in even more drops to 41.34. On the upside, there is a resistance level at 43.48. A further resistance level may holdings at 43.96. The Relative Strength Index (RSI) on the 14-day chart is 41.59, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.57, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 60.69%. Stochastics %K at 40.19% indicates the stock is a holding.
The most recent change occurred on April 26, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $114 price target.
